Moderna Aktie

Moderna für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A2N9D9 / ISIN: US60770K1079

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
12.12.2023 14:59:23

Moderna Announces Changes To Operating Model To Prepare For Product Launches

(RTTNews) - Moderna, Inc. (MRNA) said Stephane Bancel, CEO of Moderna, will assume responsibility for sales and marketing in 2024. Stephen Hoge, President of Moderna, will assume responsibility for pipeline commercial strategy and for Medical Affairs. Arpa Garay, previously Chief Commercial Officer, is expected to leave Moderna in the coming months.

The company said it is focused on driving continued sales of COVID-19 vaccine and launching RSV vaccine in 2024, while also preparing to launch multiple products per year from 2025 forward. Also, the company has decided to increase executive focus on driving sales of Spikevax and the expected launch of RSV vaccine next year.

For More Such Health News, visit rttnews.com.

Analysen zu Moderna Incmehr Analysen

19.11.24 Moderna Hold Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
13.09.24 Moderna Underweight JP Morgan Chase & Co.
05.08.24 Moderna Sector Perform RBC Capital Markets
12.01.24 Moderna Outperform RBC Capital Markets
03.11.23 Moderna Buy Goldman Sachs Group Inc.
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Moderna Inc 21,56 4,03% Moderna Inc